1. professionals with a history of sars-cov-2 confirmed infection through rt-pcr or who have already presented clinical and molecular diagnosis of covid-19 prior to the study 2. individuals who have not underwent confirmatory tests for covid-19 3. breastfeeding 4. individuals with primary or acquired immunodeficiency 5. individuals affected by malignant neoplasms 6. patients treated with high-dose corticosteroids (equivalent to the prednisone dose of 20 mg/day or more) for more than two weeks 7. patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiotherapy, among others) 8. individuals with autoimmune diseases 9. dermatological conditions at the vaccine site or generalized 10. individuals under treatment for active tuberculosis 11. individuals with a history of previous tuberculosis treatment 12. individuals with febrile symptoms \[body temperature ≥ 37.5 celsius degree (ºc) in the last 48h\] 13. participation in other prevention clinical trials for covid-19 (vaccines already approved by anvisa for use by the national immunization program are not included in this item) 14. report of vaccination with live microorganism administered in the month prior to randomization 15. require that, if another vaccination with live microorganism is required, it is administered in the month following randomisation (if the other live vaccine can be administered on the same day, this exclusion criterion does not apply) 16. known anaphylactic reaction to any ingredient in bcg vaccine 17. adverse reaction prior to bcg vaccine \[significant local reaction (abscess) or suppurative lymphadenitis\] 18. bcg vaccine administered in the last year

1. professionals with a history of sars-cov-2 confirmed infection through rt-pcr or who have already presented clinical and molecular diagnosis of covid-19 prior to the study 2. individuals who have not underwent confirmatory tests for covid-19 3. breastfeeding 4. individuals with primary or acquired immunodeficiency 5. individuals affected by malignant neoplasms 6. patients treated with high-dose corticosteroids (equivalent to the prednisone dose of 20 mg/day or more) for more than two weeks 7. patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiotherapy, among others) 8. individuals with autoimmune diseases 9. dermatological conditions at the vaccine site or generalized 10. individuals under treatment for active tuberculosis 11. individuals with a history of previous tuberculosis treatment 12. individuals with febrile symptoms \[body temperature ≥ 37.5 celsius degree (ºc) in the last 48h\] 13. participation in other prevention clinical trials for covid-19 (vaccines already approved by anvisa for use by the national immunization program are not included in this item) 14. report of vaccination with live microorganism administered in the month prior to randomization 15. require that, if another vaccination with live microorganism is required, it is administered in the month following randomisation (if the other live vaccine can be administered on the same day, this exclusion criterion does not apply) 16. known anaphylactic reaction to any ingredient in bcg vaccine 17. adverse reaction prior to bcg vaccine \[significant local reaction (abscess) or suppurative lymphadenitis\] 18. bcg vaccine administered in the last year

professionals with a history of sars-cov-2 confirmed infection through rt-pcr or who have already presented clinical and molecular diagnosis of covid-19 prior to the study individuals who have not underwent confirmatory tests for covid-19 breastfeeding individuals with primary or acquired immunodeficiency individuals affected by malignant neoplasms patients treated with high-dose corticosteroids (equivalent to the prednisone dose of 20 mg/day or more) for more than two weeks patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiotherapy, among others) individuals with autoimmune diseases dermatological conditions at the vaccine site or generalized individuals under treatment for active tuberculosis individuals with a history of previous tuberculosis treatment individuals with febrile symptoms [body temperature ≥ 37.5 celsius degree (ºc) in the last 48h] participation in other prevention clinical trials for covid-19 (vaccines already approved by anvisa for use by the national immunization program are not included in this item) report of vaccination with live microorganism administered in the month prior to randomization require that, if another vaccination with live microorganism is required, it is administered in the month following randomisation (if the other live vaccine can be administered on the same day, this exclusion criterion does not apply) known anaphylactic reaction to any ingredient in bcg vaccine adverse reaction prior to bcg vaccine [significant local reaction (abscess) or suppurative lymphadenitis] bcg vaccine administered in the last year

professionals with a history of sars-cov-2 confirmed infection through rt-pcr or who have already presented clinical and molecular diagnosis of covid-19 prior to the study individuals who have not underwent confirmatory tests for covid-19 breastfeeding individuals with primary or acquired immunodeficiency individuals affected by malignant neoplasms patients treated with high-dose corticosteroids (equivalent to the prednisone dose of 20 mg/day or more) for more than two weeks patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiotherapy, among others) individuals with autoimmune diseases dermatological conditions at the vaccine site or generalized individuals under treatment for active tuberculosis individuals with a history of previous tuberculosis treatment individuals with febrile symptoms [body temperature ≥ 37.5 celsius degree (ºc) in the last 48h] participation in other prevention clinical trials for covid-19 (vaccines already approved by anvisa for use by the national immunization program are not included in this item) report of vaccination with live microorganism administered in the month prior to randomization require that, if another vaccination with live microorganism is required, it is administered in the month following randomisation (if the other live vaccine can be administered on the same day, this exclusion criterion does not apply) known anaphylactic reaction to any ingredient in bcg vaccine adverse reaction prior to bcg vaccine [significant local reaction (abscess) or suppurative lymphadenitis] bcg vaccine administered in the last year

professionals with a history of infection confirmed by sars-cov-2 or who have already presented a diagnosis of covid-19 prior to the study individuals who have not underwent confirmatory tests for covid-19 breastfeeding individuals with primary or acquired immunodeficiency individuals affected by malignant neoplasms patients treated with high-dose corticosteroids (equivalent to the prednisone dose of 20 mg/day or more) for more than two weeks patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiotherapy, among others) individuals with autoimmune diseases dermatological conditions at the vaccine site or generalized individuals under treatment for active tuberculosis individuals with a history of previous tuberculosis treatment individuals with febrile symptoms [body temperature ≥ 37.5 celsius degree (ºc) in the last 48h] participation in other prevention clinical trials for covid-19 report of vaccination with live microorganism administered in the month prior to randomization require that, if another vaccination with live microorganism is required, it is administered in the month following randomisation (if the other live vaccine can be administered on the same day, this exclusion criterion does not apply) known anaphylactic reaction to any ingredient in bcg vaccine adverse reaction prior to bcg vaccine [significant local reaction (abscess) or suppurative lymphadenitis] bcg vaccine administered in the last year

professionals with a history of infection confirmed by sars-cov-2 or who have already presented a diagnosis of covid-19 prior to the study individuals who have not underwent confirmatory tests for covid-19 breastfeeding individuals with primary or acquired immunodeficiency individuals affected by malignant neoplasms patients treated with high-dose corticosteroids (equivalent to the prednisone dose of 20 mg/day or more) for more than two weeks patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiotherapy, among others) individuals with autoimmune diseases dermatological conditions at the vaccine site or generalized individuals under treatment for active tuberculosis individuals with a history of previous tuberculosis treatment individuals with febrile symptoms [body temperature ≥ 37.5 celsius degree (ºc) in the last 48h] participation in other prevention clinical trials for covid-19 report of vaccination with live microorganism administered in the month prior to randomization require that, if another vaccination with live microorganism is required, it is administered in the month following randomisation (if the other live vaccine can be administered on the same day, this exclusion criterion does not apply) known anaphylactic reaction to any ingredient in bcg vaccine adverse reaction prior to bcg vaccine [significant local reaction (abscess) or suppurative lymphadenitis] bcg vaccine administered in the last year

1. professionals with a history of infection confirmed by sars-cov-2 or who have already presented a diagnosis of covid-19 prior to the study 2. individuals who have not underwent confirmatory tests for covid-19 3. breastfeeding 4. individuals with primary or acquired immunodeficiency 5. individuals affected by malignant neoplasms 6. patients treated with high-dose corticosteroids (equivalent to the prednisone dose of 20 mg/day or more) for more than two weeks 7. patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiotherapy, among others) 8. individuals with autoimmune diseases 9. dermatological conditions at the vaccine site or generalized 10. individuals under treatment for active tuberculosis 11. individuals with a history of previous tuberculosis treatment 12. individuals with febrile symptoms [body temperature ≥ 37.5 celsius degree (ºc) in the last 48h] 13. participation in other prevention clinical trials for covid-19 14. report of vaccination with live microorganism administered in the month prior to randomization 15. require that, if another vaccination with live microorganism is required, it is administered in the month following randomisation (if the other live vaccine can be administered on the same day, this exclusion criterion does not apply) 16. known anaphylactic reaction to any ingredient in bcg vaccine 17. adverse reaction prior to bcg vaccine [significant local reaction (abscess) or suppurative lymphadenitis] 18. bcg vaccine administered in the last year

1. professionals with a history of infection confirmed by sars-cov-2 or who have already presented a diagnosis of covid-19 prior to the study 2. individuals who have not underwent confirmatory tests for covid-19 3. breastfeeding 4. individuals with primary or acquired immunodeficiency 5. individuals affected by malignant neoplasms 6. patients treated with high-dose corticosteroids (equivalent to the prednisone dose of 20 mg/day or more) for more than two weeks 7. patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiotherapy, among others) 8. individuals with autoimmune diseases 9. dermatological conditions at the vaccine site or generalized 10. individuals under treatment for active tuberculosis 11. individuals with a history of previous tuberculosis treatment 12. individuals with febrile symptoms [body temperature ≥ 37.5 celsius degree (ºc) in the last 48h] 13. participation in other prevention clinical trials for covid-19 14. report of vaccination with live microorganism administered in the month prior to randomization 15. require that, if another vaccination with live microorganism is required, it is administered in the month following randomisation (if the other live vaccine can be administered on the same day, this exclusion criterion does not apply) 16. known anaphylactic reaction to any ingredient in bcg vaccine 17. adverse reaction prior to bcg vaccine [significant local reaction (abscess) or suppurative lymphadenitis] 18. bcg vaccine administered in the last year